Skip to main content

Table 1 Use of χ2 test to compare genotype and tumour characteristics in ER-positive patients with breast cancer

From: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Genotype

Characteristics

 

Tumour size (mm)a

Tumour stage

Nodal involvement

 

≤20

21–50

>50

II

III

0

1–3

>4

CYP3A5 (n = 663)

n (%)

  

n (%)

 

n (%)

  

*1/*1

1 (14.3)

5 (71.4)

1 (14.3)

6 (85.7)

1 (14.3)

3 (42.9)

3 (42.9)

1 (14.3)

*1/*3

28 (30.4)

59 (64.1)

5 (5.4)

83 (89.2)

10 (10.8)

27 (29.0)

45 (48.4)

21 (22.6)

*3/*3

150 (26.8)

369 (66.0)

40 (7.2)

479 (85.1)

84 (14.9)

177 (31.4)

220 (39.1)

166 (29.5)

P

0.78

  

0.57

 

0.40

  

CYP2D6 (n = 677)

        

*1/*1

132 (28.9)

294 (64.3)

31 (6.8)

393 (85.4)

67 (14.6)

142 (30.9)

194 (42.2)

124 (27.0)

*1/*4

45 (24.7)

125 (66.7)

12 (6.6)

159 (86.9)

24 (13.1)

56 (30.6)

73 (39.9)

54 (29.5)

*4/*4

9 (27.3)

21 (63.6)

3 (9.1)

29 (85.3)

5 (14.7)

10 (29.4)

14 (41.2)

10 (29.4)

P

0.83

  

0.89

 

0.98

  

SULT1A1 (n = 677)

        

*1/*1

77 (30.5)

163 (64.7)

12 (4.8)

223 (88.1)

30 (11.9)

80 (31.6)

104 (41.1)

69 (27.3)

*1/*2

79 (25.0)

209 (66.1)

28 (8.9)

269 (84.3)

50 (15.7)

85 (26.6)

142 (44.5)

92 (28.8)

*2/*2

30 (28.8)

68 (65.4)

6 (5.8)

89 (84.8)

16 (15.2)

43 (41.0)

35 (33.3)

27 (25.7)

P

0.26

  

0.41

 

0.09

  

UGT2B15 (n = 445)

        

*1/*1

38 (31.6)

71 (59.2)

11 (9.2)

99 (82.5)

21 (17.5)

41 (34.2)

41 (34.2)

38 (31.6)

*1/*2

46 (24.9)

129 (69.7)

10 (5.4)

160 (85.6)

27 (14.4)

58 (31.0)

75 (40.1)

54 (28.9)

*2/*2

40 (29.2)

82 (59.9)

15 (10.9)

110 (79.7)

28 (20.3)

37 (26.8)

68 (49.3)

33 (23.9)

P

0.18

  

0.38

 

0.18

  
  1. Results are shown as n (%). ER, oestrogen receptor. aInformation on tumour size was missing for five patients.